Zoledronic acid
- PDF / 169,272 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 179 Views
1 S
Osteonecrosis of the jaws: 2 case reports In a retrospective study of 18 patients who presented with medication-related osteonecrosis of the jaw (MRONJ) at a medical center in Netherlands between January 2003 and January 2019, two patients [ages and sexes not stated] were described, who developed MRONJ during treatment with zoledronic acid for treatment of unspecified cancer (1 patient) or osteoporosis (1 patient). The patients, who had been diagnosed with unspecified cancer (1 patient) or osteoporosis (1 patient) and who had undergone dental implantation, started receiving IV zoledronic acid, monthly (1 patient) or IV zoledronic acid, yearly (1 patient) [doses not stated]. Subsequently, therapy course of zoledronic acid was complicated by MRONJ in both the patients. Additionally, role of dental implants in development of osteonecrosis of the jaws could not be rule out [times to reactions onsets and outcomes not stated]. Pichardo SEC, et al. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ). British Journal of Oral and Maxillofacial Surgery 803500302 58: 771-776, No. 7, Sep 2020. Available from: URL: http://doi.org/10.1016/j.bjoms.2020.03.022
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
